⁶⁸Ga–Prostate-Specific Membrane Antigen Uptake in a Malignant Pleural Effusion From Metastatic Prostate Cancer After Pleurodesis

Christos Sachpekidis, MD, Ian Alberts, MBBS, Axel Rominger, MD, and Ali Afshar-Oromieh, MD

Abstract: A 76-year-old man with metastatic adenocarcinoma of the prostate presented with increasing dyspnea. After being treated initially with drainage and afterwards with pleurodesis, he was referred for ⁶⁸Ga-prostate-specific membrane antigen 11 PET/CT imaging for restaging purposes. PET/CT demonstrated extensive ⁶⁸Ga-prostate-specific membrane antigen 11 uptake in the right pleura. Histopathology confirmed the rare case of malignant pleural effusion from metastatic prostate cancer.

Key Words: ⁶⁸Ga-PSMA-11 PET/CT, pleural metastases, prostate cancer

(Clin Nucl Med 2019;00: 00-00)

Received for publication May 3, 2019; revision accepted June 8, 2019. From the Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Christos Sachpekidis, MD, Department of Nuclear Medicine, University Hospital Bern, Freiburgstrasse 4, CH 3010, Bern, Switzerland. E-mail: christos saxpe@yahoo.gr; christos.sachpekidis@insel.ch. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

- ISŠŇ: 0363-9762/19/0000-0000
- DOI: 10.1097/RLU.00000000002748

REFERENCES

- 1. Fabozzi SJ, Schellhammer PF, el-Mahdi AM. Pulmonary metastases from prostate cancer. Cancer. 1995;75:2706-2709.
- 2. Knight JC, Ray MA, Benzaquen S. Malignant pleural effusion from prostate adenocarcinoma. Respir Med Case Rep. 2014;13:24-25.
- 3. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
- 4. Sachpekidis C, Kopka K, Eder M, et al. ⁶⁸Ga-PSMA-11 dynamic PET/CT imaging in primary prostate cancer. Clin Nucl Med. 2016;41:e473-e479.
- 5. Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance ⁸Ga-PSMA-11 (HBED-CC) PÉT/CT in patients with recurrent prostate of cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44: 1258-1268.
- 6. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
- 7. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436-1443.
- 8. Sheikhbahaei S, Afshar-Oromieh A, Eiber M, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:2117-2136.



FIGURE 1. A 76-year-old patient with a history of metastatic adenocarcinoma of the prostate (Gleason score 9) initially treated with radical prostatectomy, lymphadenectomy, and local irradiation presented with increasing dyspnea. At the time of admission, he was under androgen deprivation therapy with goserelin, and his plasma PSA level was 24.7 ng/mL. CT revealed a marked pleural effusion, which was initially treated with drainage. Afterward, he underwent pleural biopsy and pleurodesis via thoracoscopy. For restaging purposes, the patient was examined with ⁶⁸Ga–prostate-specific membrane antigen 11 (PSMA-11) PET/CT. The scans showed a diffuse, intensive tracer accumulation in the pleura, as well as multiple retroperitoneal, mediastinal, and supraclavicular PSMA-avid lymph node metastases as well as an osseous metastasis in the 12th thoracic vertebra. Histopathologic results from the pleura revealed malignant effusion from metastatic prostate adenocarcinoma. Prostate cancer most frequently metastasizes to regional lymph nodes and bones. Pulmonary metastases appear with a low incidence.' Moreover, pleural malignant effusions represent a very rare manifestation of the disease²; therefore, the gathered experience concerning pleural metastases depicted with PSMA-ligand PET is necessarily limited. The role of pleurodesis in the pleural PSMA-ligand uptake in this patient cannot be determined. Although the main indication of PSMA-ligand PET/CT lies in the assessment of prostate cancer in the biochemical relapse setting, the modality is increasingly gaining importance also in the initial staging of the intermediate- and high-risk disease as well as in the restaging of metastatic disease.3-7 It is estimated that PSMA-ligand PET/CT can dictate a change in therapeutic management of up to 54% of prostate cancer patients.⁸ The patient presented here showed disease progression under goserelin with pleural, lymph node, and osseous metastases depicted on PET/CT. As a consequence, his treatment was stopped and was changed to enzalutamide.

2 www.nuclearmed.com

© 2019 Wolters Kluwer Health, Inc. All rights reserved.